The recent approval of Pfizer's non-small cell lung cancer treatment Xalkori along with a companion test developed by Abbott Molecular serves as the latest example of how drug and diagnostic developers can use pharmacogenomic strategies to speed up drug development.

Xalkori's approval as an orphan drug also represents the successful use of available regulatory incentives to develop a drug that meets the unmet needs of a small, genomically defined patient subpopulation.

Get the full story with GenomeWeb Premium

Only $95 for the first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

This webinar will discuss the benefits of a rapid targeted next-generation sequencing (TNGS) panel, using dried blood spots, for second-tier newborn metabolic and hearing loss screening and its immediate utility for high-risk diagnostic testing in the neonatal intensive care unit.